Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase

被引:79
作者
Guo, Song [1 ,2 ]
Olesen, Jes [1 ,2 ]
Ashina, Messoud [1 ,2 ]
机构
[1] Univ Copenhagen, Fac Hlth & Med Sci, Glostrup Hosp, Danish Headache Ctr, DK-2600 Glostrup, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Glostrup Hosp, Dept Neurol, DK-2600 Glostrup, Denmark
关键词
migraine; cilostazol; headache; cyclic adenosine monophosphate; phosphodiesterase inhibitor; GENE-RELATED PEPTIDE; CEREBRAL-ARTERIES; ADENYLATE-CYCLASE; PACAP RECEPTOR; NITRIC-OXIDE; SILDENAFIL; CGRP; EXPRESSION; TADALAFIL; HEADACHE;
D O I
10.1093/brain/awu244
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The initiating mechanisms of migraine attacks are very complex but may involve the cyclic AMP signalling pathway. It is unknown whether intracellular cyclic AMP accumulation induces migraine attacks. We investigated whether administration of cilostazol, which causes cyclic AMP accumulation, may induce migraine attacks. We included 14 migraine patients without aura in a double-blind, placebo-controlled crossover study. All participants received oral cilostazol or placebo on two separate days. We recorded migraine headache characteristics, associated symptoms and time of rescue medication intake using a questionnaire. Cilostazol induced delayed migraine-like attacks in 12 patients (86%) compared with two (14%) patients after placebo (P = 0.002). The median time to onset for migraine-like attacks was 6 h (range 3-11 h). Patients reported that the attacks mimicked their usual migraine attacks and that cilostazol-induced attacks responded to their usual migraine treatment. Median time of medication intake was 6 h (range 4-11 h). The present study suggests that intracellular cyclic AMP accumulation plays a crucial role in migraine induction. This knowledge is a further step in our understanding of the intracellular pathway of migraine initiation.
引用
收藏
页码:2951 / 2959
页数:9
相关论文
共 42 条
  • [1] The International Classification of Headache Disorders, 3rd edition (beta version)
    Bes, Andre
    Kunkel, Robert
    Lance, James W.
    Nappi, Giuseppe
    Pfaffenrath, Volker
    Rose, Frank Clifford
    Schoenberg, Bruce S.
    Soyka, Dieter
    Tfelt-Hansen, Peer
    Welch, K. Michael A.
    Wilkinson, Marica
    Olesen, Jes
    Bousser, Marie-Germaine
    Diener, Hans-Christoph
    Dodick, David
    First, Michael
    Goadsby, Peter J.
    Goebel, Hartmut
    Lainez, Miguel J. A.
    Lance, James W.
    Lipton, Richard B.
    Nappi, Giuseppe
    Sakai, Fumihiko
    Schoenen, Jean
    Silberstein, Stephen D.
    Steiner, Timothy J.
    Olesen, Jes
    Bendtsen, Lars
    Dodick, David
    Ducros, Anne
    Evers, Stefan
    First, Michael
    Goadsby, Peter J.
    Hershey, Andrew
    Katsarava, Zaza
    Levin, Morris
    Pascual, Julio
    Russell, Michael B.
    Schwedt, Todd
    Steiner, Timothy J.
    Tassorelli, Cristina
    Terwindt, Gisela M.
    Vincent, Maurice
    Wang, Shuu-Jiun
    Olesen, J.
    Evers, S.
    Charles, A.
    Hershey, A.
    Lipton, R.
    First, M.
    [J]. CEPHALALGIA, 2013, 33 (09) : 629 - 808
  • [2] The headache-inducing effect of cilostazol in human volunteers
    Birk, S.
    Kruuse, C.
    Petersen, K. A.
    Tfelt-Hansen, P.
    Olesen, J.
    [J]. CEPHALALGIA, 2006, 26 (11) : 1304 - 1309
  • [3] The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow
    Birk, S
    Kruuse, C
    Petersen, KA
    Jonassen, O
    Tfelt-Hansen, P
    Olesen, J
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2004, 24 (12) : 1352 - 1358
  • [4] Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries
    Birk, S
    Edvinsson, L
    Olesen, J
    Kruuse, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 489 (1-2) : 93 - 100
  • [5] Bjorkman David J., 1998, American Journal of Medicine, V105, p8S, DOI 10.1016/S0002-9343(98)00069-2
  • [6] Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease
    Bramer, SL
    Forbes, WP
    Mallikaarjun, S
    [J]. CLINICAL PHARMACOKINETICS, 1999, 37 (Suppl 2) : 1 - 11
  • [7] Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats
    Choi, JM
    Shin, HK
    Kim, KY
    Lee, JH
    Hong, KW
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03) : 787 - 793
  • [8] Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)
    Degerman, E
    Belfrage, P
    Manganiello, VC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (11) : 6823 - 6826
  • [9] A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in VPAC/PAC receptor pharmacology
    Dickson, Louise
    Aramori, Ichiro
    McCulloch, James
    Sharkey, John
    Finlayson, Keith
    [J]. NEUROPHARMACOLOGY, 2006, 51 (06) : 1086 - 1098
  • [10] VPAC and PAC receptors: From ligands to function
    Dickson, Louise
    Finlayson, Keith
    [J]. PHARMACOLOGY & THERAPEUTICS, 2009, 121 (03) : 294 - 316